Purchase EDTA Chelation Therapy - order online

What is Chelation?

A chelate is a chemical compound in which the central atom (usually a metal ion) is attached to neighboring atoms by at least two bonds in such a way as to form a ring. Chelating is the process in which the metal ion reacts with another molecule to form the chelate. EDTA (ethylene diamine tetraacetic acid) is a synthetic amino acid commonly used in Chelation Therapy to help remove calcium deposits and other harmful minerals that promote blood clotting and atherosclerosis. Since these harmful deposits are also known to cause excessive free radical production, EDTA chelation also functions as a powerful free radical scavenger, protecting cells, DNA, enzyme systems, and lipoproteins from their destructive effects. There is evidence that the primary benefits of EDTA chelation are due to its free radical-fighting effects and the enhancement of your cells' mitochondria and ATP production.

What is Chelation Therapy?

The American Heart Association (AHA) recognizes chelation therapy as a treatment for heavy metal poisoning. In fact, EDTA is the standard FDA approved treatment for lead, mercury, aluminum, and cadmium poisoning, but the FDA does not yet acknowledge that chelation is a safe and effective treatment for heart disease. Presently, the NIH is conducting a 5 year clinical trial to determine if Chelation Therapy should be recognized as a standard treatment for various cardiovascular disorders.

Although not yet accepted as a traditional treatment for Coronary Artery Disease (CAD) as are invasive procedures like balloon angioplasty or bypass surgery, Chelation Therapy is becoming ever more popular. Nearly a million patients received some form of Chelation Therapy last year as treatment for CAD, and the numbers are growing annually.

Standard EDTA chelation therapy is a process whereby a solution of EDTA is administered intravenously to patients over several weeks to bind unwanted calcium and remove plaque from the arterial walls. Additionally, many patients take EDTA orally over a longer period to achieve the same goal.

What is Oral Chelation?

Oral Chelation is a therapy wherein EDTA is taken orally in potencies between 1,000 and 3,000 mg. per day. Depending on dosage, 3 to 4 weeks of oral chelation therapy is equivalent to a single intravenous chelation procedure. While a somewhat longer term is required for oral chelation, because less is absorbed into the system, the cost is much lower than the intravenous procedure and far easier to adhere to. It is also less invasive and more convenient since it can be administered at home.

Oral chelation with EDTA should be spread out throughout the day and include vitamin and mineral supplements as part of the therapy. EDTA has a half life of approximately 40-45 minutes. This means that the EDTA is absorbed and completes its cycle throughout the entire body in about one hour. By extending the doses throughout the day the EDTA has a greater chance of saturating the cell walls for a longer period of time and diffusing the unwanted minerals and metals. Contrary to common belief, stomach pH, acid and digestive enzymes do not damage Free Form Amino Acids such as EDTA. Free Form Amino Acids need no digestive process, as they are already small enough molecules to enter the bloodstream immediately.

Recommended Vitamins and Minerals

Increased doses of both Vitamin C and Vitamin E are recommended while on an oral chelation program. Vitamin C is a powerful antioxidant which serves as a key immune system nutrient and a potent free-radical fighter. The Vitamin C antioxidant neutralizes free radicals by donating one of their own electrons, ending a free radical chain reaction and allowing the arteries to heal.

Vitamin E is a powerful antioxidant that helps prevent oxidation of lipoproteins and reduces stickiness of platelets in the bloodstream. Vitamin E keeps arteries flexible and elastic, allowing blood to flow freely. Vitamin E acts much like Vitamin C by donating itself to a hostile free radical so it no longer acts as a threat. This makes Vitamin C and Vitamin E very important during the chelation process.

Since EDTA will also attach to some of the beneficial minerals you need for normal bodily function, it is recommended that you include a daily mineral supplement. Nutritional supplements and your main meals should be consumed at least 2 hours before or after taking EDTA orally. This will assure that the minerals you require for daily nutrition are not interfered with and the EDTA is free to chelate to toxic or misplaced metals.

Term of Treatment

Oral chelation therapy is generally conducted in 6 week intervals where the patient takes EDTA daily for 6 weeks and then goes off the supplement for a 1 or 2 week period. The break between therapy sessions helps the body balance vitamin and mineral levels before the next session. The over all term of a therapy may be from 6 to 12 months, depending on severity of symptoms and results. All chelation therapy treatments, whether intravenous or oral, should be conducted only after consultation with a health practitioner.

Other Benefits and EDTA Chelation Information

Safety and Contraindications

•   Prevents cholesterol deposits, Reduces blood cholesterol levels, Lowers high blood pressure, Avoids by-pass surgery , Avoids angioplasty, Eliminates heavy metal toxicity, Removes calcium from atherosclerotic plaques, Makes arterial walls more flexible, Reduces rheumatoid arthritis symptoms, Reduces Alzheimer-like symptoms, Reduces stroke/heart attack after-effects, Improves heart function, Reduces heart valve calcification, Reduces varicose veins.

Safety and Contraindications

EDTA Chelation therapy appears to be extremely safe, but as with almost any drug or supplement, there are potential adverse effects of EDTA chelation. One danger is nephrotoxicity (kidney damage). This is dependent on the dose, the rate of infusion, the patient's kidney function, and the patient's body burden of toxic heavy metals. In the past, kidney damage has been generally associated only with high dosage, intravenous chelation therapy.

Other potential adverse effects include hypocalcemia (excessively low blood levels of calcium) due to EDTA's binding excessively with calcium in the blood and hypoglycemia (low blood sugar), believed to be due to accompanying hypocalcemia.

Chelation with EDTA is not recommended for pregnant or nursing (lactating) women. Medications should be taken at least 3 hours before or after consumption of EDTA. Consult your health practitioner before beginning any chelation therapy to see if you are a reasonable candidate for the treatment and to make sure there is no conflict with your medications.

National Institute of Health (NIH) Study in Progress

Currently, the NIH is conducting a 5 year study with over 2,350 subjects who have had a heart attack, to determine if chelation therapy should be added to the list of proven treatments for coronary artery disease. These are their comments:

The National Center for Complementary and Alternative Medicine (NCCAM) and the National Heart, Lung, and Blood Institute (NHLBI), components of the National Institutes of Health (NIH), have launched the first large-scale clinical trial to determine the safety and efficacy of EDTA chelation therapy in individuals with coronary artery disease, the leading cause of death for both men and women in the United States

Over 800,000 patient visits were made for chelation therapy in the United States in 1997. Chelation therapy involves the use of EDTA (ethylene diamine tetra-acetic acid), a synthetic amino acid that is administered intravenously (through the veins). EDTA, which effectively speeds removal of heavy metals and minerals such as lead, iron, copper, and calcium from the blood, is approved by the U.S. Food and Drug Administration (FDA) for use in treating lead poisoning and toxicity from other heavy metals. Although it is not approved by the FDA to treat coronary artery disease, some physicians and alternative medicine practitioners have recommended EDTA chelation as a way to treat this disorder.

Coronary artery disease (CAD) is a type of heart disease in which the coronary arteries (vessels that supply oxygen-carrying blood to the heart) become blocked by deposits of a fatty substance called plaque. As plaque builds, the arteries become narrower and less oxygen and nutrients are transported to the heart for proper function. CAD can lead to serious health problems such as angina (pain caused by insufficient oxygen-carrying blood reaching the heart) and heart attack.

There are standard and well-proven ways to reduce the risks or complications of CAD. These include stopping smoking and controlling high blood pressure and high blood cholesterol through lifestyle changes and medication. More invasive procedures are used to treat symptomatic CAD including balloon angioplasty (dilation of a blocked artery to open it up) or coronary artery bypass surgery (using arteries or veins from other areas of the body to create detours for blood flow around areas of blockage in the heart artery).

"NCCAM's leadership in initiating and supporting this study is to be commended," said NHLBI Director Claude Lenfant, M.D. "It is important for heart disease patients to know whether we should add chelation therapy to the list of proven treatments for coronary artery disease. Scientific evidence is needed to resolve this issue. And only a large clinical trial can definitively answer the question of whether chelation treatment is truly safe and effective," added Lenfant.

The randomized, double-blind study will enroll 2,372 patients aged 50 or older who have had a heart attack. The $30 million study, led by Gervasio A. Lamas, M.D., director of cardiovascular research and academic affairs at Mount Sinai Medical Center-Miami Heart Institute in Miami Beach, Florida, will test whether EDTA chelation therapy and/or high-dose vitamin therapy is effective for the treatment of CAD. Vitamin and mineral supplements, consistent with the regimen used by practitioners who deliver EDTA chelation therapy, will be used in the study

References:

1. EDTA Chelation: A Misunderstood Therapy for Atherosclerosis and Other Diseases, by Ward Dean, MD, August 1997, VRP Library

2. Clarke NE, Clarke CN, Mosher RE. Treatment of angina pectoris with disodium ethelyne diamene tetraacetic acid. Am J Med Sci. 1956: December: 654-666.

3. Meltzer LE, Ural E, Kitchell JR. The treatment of coronary artery heart disease with disodium EDTA. In: Seven M, ed. Metal-Binding in Medicine, Philadelphia: JB Lippincott: 1960.

4. Hancke, C. and Flytlie, K, Benefits of EDTA Chelation Therapy in Arteriosclerosis: A retrospective study of 470 patients, Journal of Advancement in Medicine, 1993, 6:3, 161-171.

5. Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Natl Med Assoc 1990; 82:173-174.

6. Hancke C, Flytie K. Benefits of EDTA chelation therapy on arteriosclerosis. J Adv Med. 1993; 6:161-172.

7. Chappell LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J Cardiovasc Nurs. 1996; 10:78-86.

Born, G.R., and Geurkink, T.L. Improved peripheral vascular function with low dose intravenous ethylene diamine tetraacetic acid (EDTA). Townsend Letter for Doctors. July, 1994, # 132, 722-726